Mirtazapine

Drug Profile

Mirtazapine

Alternative Names: Avanza; Azamianserin; ME-2040; Mepirzapin; Norset; ORG-3770; Promyrtil; Reflex; Remergil; Remergon; Remeron; RemeronSolTab; Rexer; Zispin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Organon
  • Developer Meiji Seika Pharma; Merck & Co
  • Class Dibenzazepines; Tetracyclic antidepressants
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Serotonin 2 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Fibromyalgia

Most Recent Events

  • 01 Oct 2015 Phase-II development is ongoing for Fibromyalgia in Japan (PO) (Meiji Seika Pharma pipeline, October 2015)
  • 31 Oct 2014 Meiji Seika Pharma completes a phase II trial in Fibromyalgia in Japan (JapicCTI-122005)
  • 31 Mar 2013 Mirtazapine is still in phase II trials for Fibromyalgia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top